Bausch + Lomb Will Present New Scientific Data at American Academy of Optometry Annual Meeting

VAUGHAN, Ontario, Oct. 31, 2024 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced two podium and 17 poster presentations during the American Academy of Optometry annual meeting, taking place in Indianapolis November 6-9, 2024. The company will also host several education events.

The podium presentations will feature new scientific data on Bausch + Lomb INFUSE® and Bausch + Lomb INFUSE® for Astigmatism daily disposable contact lenses. Poster presentations will feature clinical insights on Blink™ NutriTears® clinically proven supplement for dry eyes*, Blink® Triple Care lubricating eye drops, MIEBO® (perfluorohexyloctane ophthalmic solution), XIIDRA® (lifitegrast ophthalmic solution) 5%, LUMIFY EYE ILLUMINATIONS™ and LUMIFY® Preservative Free redness reliever eye drops, which received FDA approval in April 2024 and will launch in the U.S. in 2025.

Following is a complete list of titles and authors for each presentation:

Podium Presentations

  • “Orientation Characteristics of a Novel Daily Disposable Silicone Hydrogel Toric Contact Lens”. Schafer J.
  • “Vision and Comfort Performance of a Daily Disposable Contact Lens Among Excessive Digital Device Users.” Giedd K.

Poster Presentations

  • “Adherence and Patient Characteristics of Early Adopters of Perfluorohexyloctane in Dry Eye Disease.” Alexander A.
  • “Global Pharmacovigilance Data Support the Safety Profile of Brimonidine Tartrate Ophthalmic Solution 0.025%.” Wesley G.
  • “Comparison of a Novel Lipid Nano-Emulsion Eye Drop with an Existing Non-Lipid Containing Eye Drop.” Coats J. 
  • “Clinical Evaluation of a Multi-Ingredient Oral Supplement on Dry Eye Symptoms and Tear Volume.” Gioia N.
  • “Does Lifitegrast Improve Symptoms of Discomfort and Dryness in Symptomatic Contact Lens Wearers?” Schulze M.
  • “Efficacy of Perfluorohexyloctane Ophthalmic Solution in Patients with Dry Eye Disease Stratified by Baseline Severity.” Devries D.
  • “Exploring Optometrists Educational Needs Related to Aesthetic/Cosmetic Products’ Impact on Ocular Health”. Tsai J.
  • “Evaluation of the Efficacy and Safety of a Novel Preservative-Free Formulation of Brimonidine Tartrate Ophthalmic Solution.” Wesley G.
  • “Eyecare Professional and Patient Satisfaction with Lifitegrast: Results from a Real-World Study.” Barnett M.
  • “Examining Usage Patterns of Lifitegrast in Individuals with Dry Eye Disease Associated with Other Conditions.” Schweitzer J.
  • “Perfluorohexyloctane Ophthalmic Solution Instillation Comfort and Eyedrop Acceptability: Patient-Reported Outcomes in Phase 3 Clinical Studies.” Fahmy A.
  • “Real World Evaluation of a Novel Multi-Purpose Solution in Soft Contact Lens Users.” Shahidi A.
  • “Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers.” Pennell G.
  • “Safety of Lifitegrast in Patients with Dry Eye Disease: Analysis of a Postmarketing Database.” Quint J.
  • “The Effect of Lifitegrast 5.0% Solution on Clinical Signs and Biomarkers in Dry Eye Disease.” Thimons J.
  • “Visualization of Perfluorohexyloctane, an Eye Drop for Dry Eye Disease, on the Human Ocular Surface Using Infrared Emissivity.” Borchman D.
  • “Visual Performance of a Novel Daily Disposable Silicone Hydrogel Toric Contact Lens” Schafer J.

Education Events

Wednesday, November 6
A Family of Eye Care Products for Different Stages of Life

  • 12:00-1:00 p.m. ET; Indiana Convention Center (110 S Capitol Avenue, Indianapolis; Room 108)
  • Speakers: Julie Poteet, OD, MS, CNS, FOWNS; Gina Wesley, OD, MS, FAAO; Walter O. Whitley, OD, MBA, FAAO

Showcasing Inflammation and IOP Control with Bausch + Lomb

  • 7:00-9:00 p.m. ET; Prime 47 (47 S Pennsylvania Street, Indianapolis)
  • Speakers: Marc Bloomenstein, OD, FAAO; Nora Cothran, OD, FAAO
  • Register in advance

Thursday, November 7
Innovations in Inflammation and IOP Control

  • 8:00-8:45 a.m. ET; JW Marriot Indianapolis Hotel (10 S. West Street, Indianapolis; Room White River G)
  • Speakers: Jessica Steen OD, FAAO, Dipl-ABO; Derek Cunningham OD, FAAO

Rethinking Dry Eye Disease: A Contemporary Approach to a Complex Condition

  • 12:00-1:00 p.m. ET; JW Marriot Indianapolis Hotel (10 S. West Street, Indianapolis; Room 103)
  • Speakers: James Deom, OD, MPH, FAAO, FSLS; Selina R. McGee, OD, FAAO

Racing Ahead: An Engaging Experience with a Trackside Challenge with Blink NutriTears, MIEBO, XIIDRA and INFUSE

  • 6:00-8:00 p.m. ET; Commission Row (110 Delaware Street, Indianapolis)
  • Speakers: Crystal Brimer, OD, FAAO; Mile Brujic, OD, FAAO; Gina Wesley, OD, MS, FAAO
  • Register in advance

Ocular Wellness and Nutrition Society (OWNS) Annual Reception, which is sponsored by Bausch + Lomb and Include a Presentation on Blink NutriTears and PreserVision® AREDS 2 Eye Vitamins

  • 7:00-9:30 p.m. ET; JW Marriot Indianapolis Hotel (10 S. West Street, Indianapolis; Room White River G)
  • 8:40-9:00 p.m. ET Blink NutriTears and PreserVision AREDS 2 eye vitamins presentation
  • Speaker: Julie Poteet, OD, MS, CNS, FOWNS

Friday, November 8
NEW Blink NutriTears - Clinically Proven Supplement for Dry Eyes* from Bausch + Lomb

  • 8:00-8:45 a.m. ET; JW Marriot Indianapolis Hotel (10 S. West Street, Indianapolis; Room White River G)
  • Speakers: Cecelia Koetting, OD, FAAO, Dipl ABO; Julie Poteet, OD, MS, CNS, FOWNS

The Puzzle of Dry Eye: Targeted Approaches to A Multifactorial Condition with Blink NutriTears, MIEBO and XIIDRA

  • 12:00-1:00 p.m. ET; Indiana Convention Center (110 S Capitol Avenue, Indianapolis; Room 103)
  • Speakers: Paul M. Karpecki, OD, FAAO; Selina R. McGee, OD, FAAO

INDICATION
MIEBO (perfluorohexyloctane ophthalmic solution) is used to treat the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

  • Patients should remove contact lenses before using MIEBO and wait for at least 30 minutes before reinserting.
  • It is important for patients to use MIEBO exactly as prescribed.
  • It is not known if MIEBO is safe and effective in children under the age of 18.
  • The most common eye side effect seen in studies was blurred vision (1% to 3% of patients reported blurred vision and eye redness).

Click here for full Prescribing Information for MIEBO.

Indication
XIIDRA (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

  • XIIDRA is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.
  • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.
  • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.
  • Contact lenses should be removed prior to the administration of XIIDRA and may be reinserted 15 minutes following administration.
  • Safety and efficacy in pediatric patients below the age of 17 years have not been established.

Click here for full Prescribing Information for XIIDRA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on X, LinkedIn, Facebook and Instagram.

*This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

References 

  1. Keenan TDL, Agrón E, Keane PA, et al. Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration. Ophthalmology. Published online July 16, 2024. doi:10.1016/j.ophtha.2024.07.014

© 2024 Bausch + Lomb.
MTB.0470.USA.24 

Media Contact:
Kristy Marks
[email protected]
(908) 927-0683

Caryn Marshall
[email protected]
(908) 493-1381

 

Investor Contact:
George Gadkowski
[email protected]
(877) 354-3705 (toll free)
(908) 927-0735

Back to Press Releases